Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 9/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | UBE2N | P61088 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30825266 | 1.00 | HTR6 (0.44) | HTR6L3MBTL1MAPTMEN1KMT2A | |
| SCHEMBL31465575 | 0.76 | HTR6 (0.45) | HTR6L3MBTL1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3201151 | 0.76 | HTR6 (0.48) | HTR6L3MBTL1MAPTKDM4EUBE2N | |
| SCHEMBL17498073 | 0.75 | MAPT (0.44) | HTR6MAPTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL30825273 | 0.75 | HTR6 (0.37) | HTR6L3MBTL1MEN1KMT2AKDM4E | |
| SCHEMBL17495005 | 0.75 | HTR6 (0.51) | HTR6L3MBTL1 | |
| SCHEMBL30825255 | 0.74 | HTR6 (0.38) | HTR6L3MBTL1ALDH1A1 | |
| SCHEMBL3213248 | 0.74 | MMP2 (0.46) | L3MBTL1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL17498069 | 0.73 | USP2 (0.40) | HTR6MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15365763 | 0.72 | HTR6 (0.49) | HTR6L3MBTL1MAPTKDM4EUBE2N |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368619-A1 | SUBSTITUTED TETRAHYDROCYCLOHEPTA[E]INDOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI SA (FR) | 2025-12-04 | — | — | US | disclosed |
| EP-4584257-A1 | SUBSTITUTED TETRAHYDROCYCLOHEPTA[E]INDOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | Sanofi (FR) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024052518-A1 | SUBSTITUTED TETRAHYDROCYCLOHEPTA[E]INDOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2024-03-14 | — | — | WO | disclosed |
| WO-2016025933-A2 | SUBSTITUTED POLYCYCLIC ANTIBACTERIAL COMPOUNDS | PTC THERAPEUTICS, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368619-A1 | SUBSTITUTED TETRAHYDROCYCLOHEPTA[E]INDOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | CYP19A1, NR5A1, FSHR | HTR6 194/4885L3MBTL1 4175/4885MAPT 3211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.